The two main treatments for chronic inflammatory bowel disease are anti-TNFs and thiopurine. Researchers have shown that their use can increase the risk of lymphoma.
120,000 people are said to be affected by chronic inflammatory bowel diseases, such as Crohn’s disease, in France. Figures that have been on the rise in recent decades. Faced with this, treatments are evolving. The effectiveness of anti-TNF and thiopurine treatments has been proven. But researchers have shown that their use can increase the risk of lymphoma.
The combination of the two treatments: another risk factor
The study was published in the Journal of American Medical Association. She looked at 189,289 patients, who were followed for an average of 6 years. Some have had anti-TNF treatment, some have had thiopurine, some have taken both treatments. The researchers found that the risk of getting lymphoma was greater for people who had treatment. An even greater risk for those who took both drugs at the same time. For scientists, the results of this study show that we must remain vigilant in the face of treatments. A reflection on the advantages and disadvantages seems important for the well-being of the patients.
.
